fda semaglutide compounding warning november 2025 February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter – Partnership for Safe Medicines What is a 503B outsourcing

The Silent Threat: Chronic Inflammation and Metabolic Health Obesity and metabolic dysfunction are increasingly understood as states driven by chronic low-grade inflammation

So yes, peptides work

From the cover: ROS-induced store-operated Ca 2+ entry coupled to PARP-1 hyperactivation is independent of PARG activity in necrotic cell death

The same research team showed lower GLP-1 receptor expression on eosinophils in allergic asthmatic cohorts compared with non-asthmatic patient cohorts, while Th2 cytokine production and markers of eosinophil activation were suppressed with the use of GLP-1 analogs [91]

GLP-1 medications should be used as part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity.